News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
FREMONT, Calif. , March 16, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier , an industry
View HTML
Toggle Summary Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
FREMONT, Calif. , March 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the
View HTML
Toggle Summary Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
FREMONT, Calif , Feb. 26, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA.
View HTML
Toggle Summary Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
FREMONT, Calif. , Feb. 19, 2020 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present at the 9 th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City .
View HTML
Toggle Summary Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public
View HTML
Toggle Summary Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
The primary endpoint was met (p
View HTML
Toggle Summary Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
FREMONT, Calif. , Dec. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, December 3 , at 8:00
View HTML
Toggle Summary Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
FREMONT, Calif. , Nov. 26, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive officer of
View HTML
Toggle Summary Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
- Companies establish a research collaboration with associated options to license any resulting development candidates with the potential for up to $500 million in development and sales milestones for Ardelyx - In addition, Kyowa Kirin makes $20 million equity investment in Ardelyx FREMONT, Calif.
View HTML